Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Journal of Endocrinological Investigation
|
May 14, 2013
Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism
B Aktas Yılmaz, A Akyel, E Kan, et al.
European Journal of Cancer Care
|
April 2, 2015
Depression and socio-economical burden are more common in primary caregivers of patients who are not aware of their cancer: TURQUOISE Study by the Palliative Care Working Committee of the Turkish Oncology Group (TOG)
O Tanriverdi, T Yavuzsen, S Turhal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 6, 2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
M Martín, S Loibl, T Hyslop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
M Martín, S R Stecklein, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Journal of Endocrinological Investigation
|
May 14, 2013
Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism
B Aktas Yılmaz, A Akyel, E Kan, et al.
European Journal of Cancer Care
|
April 2, 2015
Depression and socio-economical burden are more common in primary caregivers of patients who are not aware of their cancer: TURQUOISE Study by the Palliative Care Working Committee of the Turkish Oncology Group (TOG)
O Tanriverdi, T Yavuzsen, S Turhal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 6, 2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
M Martín, S Loibl, T Hyslop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
M Martín, S R Stecklein, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 2